XXII
22nd Century
–
Index: NYSE; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 90.95M; Volume: 274.37K; AvgVol 3m: 975.40K; Beta: –;
Cost estimate:
P/E: –; EPS: -0.20; EPS growth quarter/prev quarter: 43.50%;
EPS growth this year: -229.20%; EPS growth past 5 years: 4.10%;
EPS ttm: -0.20;
P/S: 3.35; P/B: 1.81; P/Cashflow: 3.16; P/FCF: ;
Sales: 27.21M; Sales growth quarter/prev quarter: 10.30%; Sales growth past 5 years: 117.60%;
Profitability:
Gross Margin: 2.50%; Profit Margin: -93.80%; Operating Margin: -84.60%;
ROA – return on assets: -39.80%; ROE – return on equity: -44.50%; LT Debt/Equity: 0.01; Total Debt/Equity: 0.05;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.30%; Insider Transactions:6.03%;
Institutional Ownership: 28.30%; Institutional Transactions: -19.24%;
Data update: 07.10.2020.